Summary of Aipeng Medical Conference Call Company Overview - Aipeng Medical focuses on the commercialization of non-invasive brain-computer interfaces, particularly in intraoperative anesthesia monitoring, achieving over 10 million yuan in revenue. However, progress has been hindered by medical cost control measures, prompting the company to actively explore new applications [2][6]. Key Points and Arguments Revenue Projections - The company anticipates that new applications targeting treatment systems for refractory insomnia and multimodal ADHD could generate tens of millions of yuan in revenue by 2026, with 2027 potentially marking a turning point in performance, contingent on a solid commercialization foundation in hospitals [2][6]. Product Offerings and Market Penetration - Aipeng Medical's perioperative brain state monitoring product is available in approximately 20 provinces, charging around 300 yuan per session, and is not covered by medical insurance. Similar models are used for the refractory insomnia and pediatric ADHD treatment systems [2][7]. - The intraoperative anesthesia monitoring product has been adopted in over 100 hospitals, with a target of exceeding 200 by 2026. The refractory insomnia treatment system has partnered with two hospitals, while the pediatric ADHD treatment aims to cover the top 100 pediatric clinics in China [2][8]. Research and Development - A semi-invasive epilepsy warning product is in the prototype research phase, expected to have a prototype by the end of 2026 and enter animal clinical trials in 2027, collaborating with research institutions [2][9]. Strategic Partnerships - Aipeng Medical holds a stake in Ruishen An, a company focused on implantable neurostimulation devices, which has received 15 product certifications and is projected to exceed 100 million yuan in revenue by 2025, ranking among the top three to four in the domestic neurostimulation field [4][11]. Competitive Landscape - The company differentiates its strategy by focusing on pain, anesthesia, sleep, and attention disorders, contrasting with competitors that emphasize rehabilitation or motor imagery. Aipeng Medical plans to accumulate clinical validation through hospital channels before gradually promoting products to the consumer market [5][13]. - Non-invasive and semi-invasive brain-computer interface technologies each have their advantages. Non-invasive products are expected to commercialize rapidly within 2-3 years, while semi-invasive and fully implanted devices will become significant as technology advances and costs decrease [5][14]. Future Outlook - Aipeng Medical aims to enhance its stake in Ruishen An through share transfers, with expectations of results in the first half of the year, despite lengthy processes for state-owned capital exits [4][12]. - The company expects gradual recovery and stable growth in its pain management business by 2026, despite initial impacts from centralized procurement policies. The nasal care business faces challenges but is anticipated to rebound as the economy improves [15]. Additional Important Information - The company’s non-invasive products are currently not covered by medical insurance, which affects their market penetration and pricing strategy [7]. - Aipeng Medical's approach emphasizes building strong clinical data and partnerships with hospitals to establish a competitive edge in the medical field [14].

Core Insights - The "Brain-Computer Interface Technology Seminar" held in Beijing focused on the innovative applications and future development of brain-computer interface (BCI) technology in clinical medicine and rehabilitation [1][5] - The event gathered top experts and representatives from various fields, emphasizing the importance of collaboration to accelerate the clinical translation and application of BCI technology [1][5] Group 1: Expert Contributions - Experts, including Gao Xiaorong, discussed the foundational research, technological bottlenecks, and future trends of BCI technology, providing cutting-edge academic perspectives [2] - Clinical experts shared valuable practical experiences regarding the use of BCI technology in treating neurological disorders such as consciousness disorders and Parkinson's disease, highlighting its significant clinical potential [2] Group 2: Clinical Applications - Professor He Jianghong emphasized that consciousness disorders represent a key clinical application for BCI technology, which can assist patients with motor function loss in expressing intentions and accelerating rehabilitation through intelligent technology [2] - The use of brain signal detection devices in conjunction with exoskeleton machines has shown superior results compared to passive rehabilitation methods [2] Group 3: Industry and Innovation - Zhang Cheng from Beijing Dako Brain Link Technology Co., Ltd. presented advancements in neuro-regulation and human-computer interaction devices aimed at severely disabled and dementia patients, addressing significant unmet clinical needs [4] - The seminar facilitated in-depth discussions on the pathways for the commercialization and industrialization of BCI technology, with a consensus on the necessity of breaking down barriers and creating an efficient collaborative innovation ecosystem [5] Group 4: Future Directions - The event served as a high-end platform for collaboration in the BCI field, outlining the application prospects and development directions of this technology in the future healthcare industry [5] - Participants expressed intentions to strengthen cross-disciplinary cooperation to promote innovation and development in neuro-regulation and human-computer interaction technologies for the benefit of patients [5]